the subsequent interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy
the subsequent interim data analysis of the sputnik v vaccine against covid-19 phase iii clinical trials in the russian federation demonstrated 92 % efficacy
gamaleya of the ministry of health of the russian federation (gamaleya center) and the russian direct investment fund (rdif, russias sovereign wealth fund), announce that the sputnik v vaccine, the world's first registered vaccine against coronavirus (registered on the 11th of august under the emergency use authorization mechanism) created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy.